Logo

Eli Lilly Reports the Availability of Taltz (ixekizumab) as New Citrate-Free Formulation to Reduce Injection Site Pain in the US

Share this
Eli Lilly Reports the Availability of Taltz (ixekizumab) as New Citrate-Free Formulation to Reduce Injection Site Pain in the US

Eli Lilly Reports the Availability of Taltz (ixekizumab) as New Citrate-Free Formulation to Reduce Injection Site Pain in the US

Shots:

  • Taltz has been approved in the US in May 2022 to treat adults & children aged ≥6yrs. with PsO, PsA, AS & nr-axSpA with objective signs of inflammation. The therapy is now available as a citrate-free formulation with an effective treatment along with a well-established safety profile in the US
  • The new formulation showed a reduction in injection site pain and an 86% reduction in a visual analog scale (VAS) of pain over the original formulation. The safety profile was consistent with the original formulation
  • The new formulation is expected to be available for new and existing Taltz patients at the end of Aug 2022. The new formulation has been approved by the EMA in Dec 2021

Ref: PR Newswire | Image: Lilly

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions